JPMorgan Upgrades Replimune to Overweight on FDA Path
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
replimunebiotech
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
JPMorgan Chase & Co. upgraded its rating on Replimune Group Inc. stock to Overweight from Neutral on June 1, 2026, following clarity on a regulatory pathway for the company's lead candidate, RP1. Analyst Eric Joseph established a price target of $35, implying significant upside from the stock's recent trading levels. The upgrade reflects analyst conviction that the biotech firm can successfully resubmit its Biologics License Application to the U.S. Food and Drug Administration for the treatment of advanced cutaneous squamous cell carcinoma. JPMorgan shares traded at $299.31, up 0.01% on the day, as the firm's research arm issued the bullish call.
The upgrade arrives after a prolonged period of regulatory uncertainty for Replimune. The FDA issued a Complete Response Letter for RP1 in December 2025, requesting additional clinical data. The agency has now provided specific guidance on the required supplementary information, creating a defined resubmission timeline. This development is critical within the current biotech investment landscape, where regulatory clarity often drives valuation more than clinical data alone. The sector has underperformed the broader market, with the SPDR S&P Biotech ETF (XBI) down approximately 15% year-to-date against the S&P 500's gains. Successful oncology drug approvals represent one of the few catalysts capable of generating multibillion-dollar market cap moves for small and mid-cap biotech firms. The last major comparable event occurred in August 2025, when Karuna Therapeutics surged 65% in a single session following positive FDA advisory committee comments for its schizophrenia treatment.
Replimune's stock price reacted positively to the upgrade news, rising approximately 4.2% in premarket activity. This move contrasts sharply with its performance over the past year, where the stock declined over 60% from its 2025 highs following the FDA's Complete Response Letter. JPMorgan's $35 price target represents a potential 150% increase from the stock's closing price prior to the announcement. The bank's upgrade places Replimune in a small cohort of biotech stocks with Overweight ratings from JPMorgan, which covers over 85 companies in the sector. For comparison, the broader iShares Nasdaq Biotechnology ETF (IBB) has a price-to-earnings ratio of 18.7, while Replimune, as a pre-commercialization company, trades on future revenue potential rather than current earnings. The company reported $285 million in cash and equivalents as of its last quarterly filing, providing an estimated 24 months of runway at current burn rates.
The upgrade signals institutional confidence in the regulatory process for oncology therapies, potentially benefiting other companies with pending FDA resubmissions. Direct competitors in the cutaneous squamous cell carcinoma space, including Regeneron Pharmaceuticals with its PD-1 inhibitor Libtayo, may face increased competitive pressure if RP1 gains approval. The analysis suggests flow will move into specialty pharmaceutical and biotechnology options as traders position for potential volatility around the resubmission date. One material risk to the thesis is that the resubmission timeline extends beyond current expectations, which would delay potential commercialization and require additional capital raises. Short interest in Replimune stood at 18% of float prior to the upgrade, suggesting significant potential for a short squeeze if positive momentum continues. The upgrade may also create a halo effect for other companies in the oncolytic virus therapy space, such as Amgen and its Imlygic platform.
Investors should monitor Replimune's formal announcement of its resubmission timeline, expected within 30 days. The company's second-quarter 2026 earnings call, typically held in late July, will provide updated guidance on clinical development plans and cash position. Key technical levels to watch include the $14.50 resistance point, a breach of which could signal further upward momentum. The FDA's Prescription Drug User Fee Act (PDUFA) date, once announced, will serve as the primary catalyst for the stock. Regulatory feedback from European authorities regarding the same therapy will provide additional data points in the fourth quarter of 2026. Trading volume exceeding 3 million shares per day would indicate sustained institutional interest in the name.
The upgrade represents a significant vote of confidence from a major institutional research firm that Replimune shares are undervalued relative to their potential. It suggests analysts believe the company has addressed the FDA's concerns adequately and can manage the resubmission process successfully. For long-term investors, it may indicate reduced regulatory risk and improved probability of drug approval and subsequent commercialization.
The provided regulatory pathway appears more straightforward than many comparable cases. Unlike some Complete Response Letters that require additional clinical trials spanning years, this resubmission primarily requests analyses of existing data. This suggests the FDA's concerns were largely procedural or statistical rather than fundamental questions about efficacy or safety, which typically result in much longer resolution timelines.
Advanced cutaneous squamous cell carcinoma represents a growing market opportunity with approximately 15,000 new diagnoses annually in the United States alone. With limited effective treatment options, analysts project the market could reach $2.5 billion globally by 2028. RP1, as a potential first-in-class oncolytic viral immunotherapy, could capture significant market share if approved, particularly in patients who have failed other treatments.
JPMorgan's upgrade reflects conviction that Replimune's regulatory risk has materially decreased with a clear FDA pathway established.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.